Trans-scleral ocular drug delivery for the treatment of posterior segment eye diseases
10.3760/cma.j.issn.1005-1015.2017.02.028
- VernacularTitle:治疗眼后节疾病的经巩膜给药装置的研究现状
- Author:
Xiaoli LI
;
Lingyun CHENG
- Keywords:
Administration,ophthalmic;
Sclera;
Delayed-action preparations/therapeutic use;
Posterior eye segment;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2017;33(2):213-217
- CountryChina
- Language:Chinese
-
Abstract:
The human sclera accounts for 95％ of the surface of the eyeball,providing ample contact area which is suitable for targeted trans-scleral ocular drug delivery.Currently there are several tans-scleral sustained-release strategies,including intra-scleral delivery,episcleral delivery,as well as tans-scleral iontophoresis.Different devices and methods have their own advantages and disadvantages,for example,intrascleral delivery is somehow invasive,and episcleral delivery device needs to be made thin to prevent erosion of conjunctiva,iontophoresis needs to be frequently repeated as of its short-term effect.With the development of bio-material engineering technology,episcleral microfilm could become an ideal drug delivery route for posterior segment ocular diseases.
